trending Market Intelligence /marketintelligence/en/news-insights/trending/CePvKcaZugrGHCaZUzHRSg2 content esgSubNav
In This List

Cadila secures US FDA approval for epilepsy drug

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Cadila secures US FDA approval for epilepsy drug

Cadila Healthcare Ltd., under the aegis of Zydus Cadila, secured the U.S. Food and Drug Administration approval for Felbamate tablets.

The drug is used for the treatment of seizures in people with epilepsy.